Compare WST & LVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | LVS |
|---|---|---|
| Founded | 1923 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4B | 23.4B |
| IPO Year | 2004 | 2004 |
| Metric | WST | LVS |
|---|---|---|
| Price | $387.42 | $38.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 21 |
| Target Price | ★ $412.88 | $57.04 |
| AVG Volume (30 Days) | 412.2K | ★ 4.8M |
| Earning Date | 10-29-2026 | 10-21-2026 |
| Dividend Yield | 0.23% | ★ 3.16% |
| EPS Growth | 1.49 | ★ 19.90 |
| EPS | ★ 4.07 | 1.38 |
| Revenue | $2,886,900,000.00 | ★ $13,017,000,000.00 |
| Revenue This Year | $9.79 | $5.69 |
| Revenue Next Year | $6.29 | $5.26 |
| P/E Ratio | $94.63 | ★ $27.34 |
| Revenue Growth | 1.95 | ★ 15.22 |
| 52 Week Low | $223.83 | $35.28 |
| 52 Week High | $387.01 | $70.45 |
| Indicator | WST | LVS |
|---|---|---|
| Relative Strength Index (RSI) | 66.27 | 42.20 |
| Support Level | $346.45 | $35.28 |
| Resistance Level | N/A | $55.13 |
| Average True Range (ATR) | 8.20 | 0.79 |
| MACD | 0.93 | 0.41 |
| Stochastic Oscillator | 93.14 | 73.98 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, Sands generates all its EBITDA from Asia, with its casino operations generating the majority of sales.